NCT05757063

Brief Summary

The QT interval is a measure of the combination of cardiac depolarization and repolarization as it encompasses both the QRS complex and the J-T interval. QT, QTc, QTd prolongation or shortening has been associated with ventricular arrhythmias . In order to define non-torsogenic drug-induced arrhythmias, the index of cardio-electrophysiological balance (iCEB), which is a new marker calculated with the QT/QRS formula, has been defined. In our study, we planned to evaluate the effects of dexmedetomidine and propofol on cardiac electrophysiology with all these parameters, especially the newly defined iCEB.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 22, 2023

Completed
7 days until next milestone

Study Start

First participant enrolled

March 1, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 7, 2023

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
Last Updated

December 18, 2023

Status Verified

December 1, 2023

Enrollment Period

4 months

First QC Date

February 22, 2023

Last Update Submit

December 12, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • ICEBc

    QTc/QRS formula

    İntraoperative 10th minute

Secondary Outcomes (10)

  • ICEB

    Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute

  • ICEBc

    Baseline,İntraoperative 1th,5th,15th,30th,45th,75th minute

  • QT

    Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute

  • QTc

    Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute

  • QTd

    Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute

  • +5 more secondary outcomes

Study Arms (2)

Propofol

ACTIVE COMPARATOR

Sedation procedure with propofol

Other: Sedation with propofol

Dexmedetomidine

ACTIVE COMPARATOR

Sedation procudure with dexmedetomidine

Other: sedation with dexmedetomidine

Interventions

After spinal anesthesia, patients will be sedated with propofol.

Propofol

After spinal anesthesia, patients will be sedated with dexmedetomidine.

Dexmedetomidine

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with ASA Ⅰ-Ⅱ ,
  • years old, who will be operated under spinal anesthesia

You may not qualify if:

  • Hypersensitivity to the propofol,dexmedotimidine
  • preoperative QTc prolongation
  • preoperative heart disease
  • use of drugs that affect the QT interval
  • severe sinus bradycardia
  • preoperative electrolyte abnormalities
  • liver and kidney function abnormalities
  • non-sinus rhythm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara City Hospital

Ankara, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

PropofolDexmedetomidine

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

February 22, 2023

First Posted

March 7, 2023

Study Start

March 1, 2023

Primary Completion

July 1, 2023

Study Completion

August 1, 2023

Last Updated

December 18, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations